Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


NMPA (China) approves Symplicity Spyral renal denervation (RDN) system – Medtronic

Written by | 12 May 2024 | Cardiology

Medtronic announced it received approval from the National Medical Products Administration (NMPA) in China for its Symplicity Spyral renal denervation (RDN) system, also known as the Symplicity blood pressure procedure.

Symplicity Spyral is the first RDN system in China to receive NMPA approval. The company intends to go through the provincial registration process and expects sales of Symplicity Spyral in China to be modest in the short-term.

Hypertension is one of the most prominent public health challenges in China, with over 245 million people affected by the condition. Further, only 13.8% of those living with hypertension in China have their condition under control. Worldwide, control rates remain low, despite available medications and lifestyle interventions. These challenges speak to the possibility that patients may benefit from an adjunctive treatment option to better manage their blood pressure.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.